GLC Biotechnology, Inc. (GLC), a molecular cancer diagnostics company, is an Ohio "C"
corporation and has been engaged in the development of cancer diagnostic tests since 2006.
GLC's mission is to develop simple, accurate, affordable, and user-friendly molecular
cancer diagnostic tests that address the most pressing challenges in the early cancer
detection. GLC's vision is that our tests will provide physicians a non-invasive option to
detect early-stage cancer simply by analysis of a drop of blood, or bodily fluid, or a piece of
stool collected from patients. Currently, GLC is developing a noninvasive fecal DNA test
protected by exclusive intellectual property to target the multi-billion dollar colorectal
cancer (CRC) screening market.